NDA 020742 · Alcon
Bss
Calcium Chloride, Magnesium Chloride, Potassium Chloride, Sodium Acetate, Sodium Chloride, Sodium Citrate · Irrigation
Last checked: Nov 20, 2026Latest source record: Nov 6, 2015 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1997
Dec 10, 1997
Approved uses
1
Original approval plus efficacy supplements
Registered trials
9,299
2,122 Phase 3, 968 recruiting
FAERS reports
1,293
1,129 serious, 7 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 25, 2024.
INDICATIONS AND USAGE For use as an extraocular and intraocular irrigating solution during ocular surgical procedure involving perfusion of the eye with an expected maximum duration of less than 60 minutes.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Dec 10, 1997 Original approval · Type 4 - New Combination
1 products under this application
- BSS · CALCIUM CHLORIDE 0.48MG/ML; MAGNESIUM CHLORIDE 0.3MG/ML; POTASSIUM CHLORIDE 0.75MG/ML; SODIUM ACETATE 3.9MG/ML; SODIUM CHLORIDE 6.4MG/ML; SODIUM CITRATE 1.7MG/ML · SOLUTION, IRRIGATION · Prescription · TE AT
Clinical trials
Interventional ClinicalTrials.gov studies with "Chloride" as an intervention, any sponsor and status, largest first.
- Introduction of Cholera Vaccine in BangladeshPivotal-lookingCompleted
International Centre for Diarrhoeal Disease Research, BangladeshAcademic, hospital or other
NCT01339845 · 240,000 participants · Start Sep 2009 · Primary completion Dec 2016
Drug: ShanChol · For: Cholera
Sites: Dhaka, Bangladesh
- Vellore Typhoid Vaccine Impact TrialPivotal-lookingCompleted
Christian Medical College, Vellore, IndiaAcademic, hospital or other
NCT05500482 · 72,400 participants · Start May 1, 2023 · Primary completion Jan 31, 2026
Drug: Typhoid conjugate Vaccine · For: Typhoid Fever
Sites: Vellore, India
- Randomised Evaluation of COVID-19 TherapyPivotal-lookingRecruiting
University of OxfordAcademic, hospital or other
NCT04381936 · 70,000 participants (planned) · Start Mar 19, 2020 · Primary completion Sep 30, 2028
Drug: Lopinavir-Ritonavir; Corticosteroid and 20 more · For: Pneumonia
Sites: Brussels, Belgium; Tallinn, Estonia; Paris, France · 16 sites in all
- Protective Effect, Safety and Immunogenicity of Live Attenuated Varicella Vaccine in Anhui ProvinceStatus unknown
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05470855 · 45,400 participants (planned) · Start Jul 6, 2022 · Primary completion Nov 30, 2022
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Anqing, China; Chuzhou, China; Fuyang, China · 5 sites in all
- Crystalloid FLUID Choices for Resuscitation of Hospitalized PatientsPivotal-lookingCompleted
Ottawa Hospital Research InstituteAcademic, hospital or other
NCT04512950 · 43,626 participants · Start Aug 15, 2016 · Primary completion Jun 13, 2020
Drug: Ringer's lactate; 0.9% saline · For: Fluid Therapy
Sites: Hamilton, Canada; London, Canada; Ottawa, Canada · 7 sites in all
- Tranexamic Acid to Prevent Heavy Bleeding After Childbirth in Women at Higher RiskPivotal-lookingRecruiting
London School of Hygiene and Tropical MedicineAcademic, hospital or other
NCT05562609 · 40,000 participants (planned) · Start Apr 22, 2024 · Primary completion Sep 2027
Drug: Tranexamic acid · For: Postpartum Hemorrhage
Sites: Mbeya, Tanzania
- A Global Phase III Clinical Trial of Recombinant COVID- 19 Vaccine (Sf9 Cells)Pivotal-lookingCompleted
WestVac Biopharma Co., Ltd.Industry
NCT04904471 · 39,663 participants · Start Jun 15, 2021 · Primary completion Jan 31, 2022
Drug: Recombinant COVID-19 vaccine (Sf9 cells) · For: COVID-19
Sites: Bekasi, Indonesia; Malang, Indonesia; Surabaya, Indonesia · 24 sites in all
Sinovac (Dalian) Vaccine Technology Co., Ltd.Industry
NCT05460429 · 37,920 participants (planned) · Start Jul 30, 2022 · Primary completion Mar 15, 2023
Drug: Live attenuated varicella vaccine · For: Varicella
Sites: Chuzhou, China; Lishui, China; Quzhou, China
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- toxic anterior segment syndrome509
- endophthalmitis313
- hypopyon109
- eye inflammation100
- corneal oedema99
- off label use86
- post procedural complication79
- vision blurred74
- eye pain70
- anterior chamber cell63
- visual acuity reduced55
- visual impairment54
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 22 |
| 2005 | 3 |
| 2006 | 79 |
| 2007 | 36 |
| 2008 | 46 |
| 2009 | 36 |
| 2010 | 24 |
| 2011 | 37 |
| 2012 | 104 |
| 2013 | 83 |
| 2014 | 69 |
| 2015 | 88 |
| 2016 | 132 |
| 2017 | 116 |
| 2018 | 66 |
| 2019 | 36 |
| 2020 | 17 |
| 2021 | 58 |
| 2022 | 89 |
| 2023 | 35 |
| 2024 | 36 |
| 2025 | 51 |
| 2026 | 30 |
Recalls
2 FDA enforcement reports for this application.
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Apr 13, 2022 · Class II · Terminated
cGMP deviations: Temperature abuse
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Bss (Balanced Salt Irrig Soln No.2)
2024 spending
$3K
Beneficiaries
41
126 claims
Per beneficiary
$82
$0.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $4,792 |
| 2021 | $13,232 |
| 2022 | $10,120 |
| 2023 | $6,621 |
| 2024 | $3,362 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Effects of dietary fibers or probiotics on functional constipation symptoms and roles of gut microbiota: a double-blinded randomized placebo trial.
Lai H, Li Y, He Y, et al. · Gut Microbes 2023 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Probiotics for constipation and gut microbiota in Parkinson's disease.
Du Y, Li Y, Xu X, et al. · Parkinsonism Relat Disord 2022 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
- Resuscitation with blood products in patients with trauma-related haemorrhagic shock receiving prehospital care (RePHILL): a multicentre, open-label, randomised, controlled, phase 3 trial.
Crombie N, Doughty HA, Bishop JRB, et al. · Lancet Haematol 2022 · Clinical Trial, Phase III, Multicenter Study
- Functional near-infrared spectroscopy as a biomarker of TMS efficacy in treatment-resistant depression.
Lin CE, Chen LF, Chung CH, et al. · Psychiatry Clin Neurosci 2025 · Randomized Controlled Trial
- Heparin Versus Saline: A Comparative Study to Support Practice Change Within an Organization.
Denke L, Allen M, Atem F, et al. · J Infus Nurs 2025 · Comparative Study, Randomized Controlled Trial
- Efficacy of Dequalinium Chloride vs Metronidazole for the Treatment of Bacterial Vaginosis: A Randomized Clinical Trial.
Raba G, Durkech A, Malík T, et al. · JAMA Netw Open 2024 · Randomized Controlled Trial, Research Support, Non-U.S. Gov't
Sponsor: Alcon
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.